Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasradiotherapyTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupunfitICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C88.0-C91.0-C91.1-MeSHLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceCELESTIMO: MOSU(1/2/30), foll. Lymphoma °I-IIIa, C1 (PID2075) -|- MOSU30/LENA20, foll. Lymphoma °I-IIIa, C2-12 (PID2076)CELESTIMO: RITU375/LENA20, foll. Lymphoma °I-IIIa, C1 (PID2077) -|- C2 (PID2079) -|- C3 (PID2078) -|- C4 (PID2079) -|- C5(PID2078) -|- C6 (PID2079) -|- C7 (PID2078) -|- C8 (PID2079) -|- C9(PID2078) -|- C10 (PID2079) -|- C11 (PID2078) -|- C12 (PID2079)EPCO(0.16/0.8/3/48), foll. Lymphoma, C1 (PID2723) -|- EPCO48, C2-3 (PID2724) -|- C4-9 (PID2725) -|- C10+ (PID2726)GADOLIN: OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1 (PID710) -|- C2-6 (PID724) -|- maint. (PID725)GALEN: OBIN1000/LENA20, foll. Lymphoma °I-IIIa, C1 (PID2336) -|- C2-6 (PID2337) -|- C7-12 (PID2338) -|- C13-18 (PID2339)GAUSS: OBIN1000, B-NHL, Ind. (PID2340) -|- OBIN1000, B-NHL, maint. (PID2341)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)OBIN-CHOP (OBIN1000/CYCL750/DOXO50/VNCR2/PRED100), foll. Lymphoma °I-IIIa, C1 (PID1171) -|- C2-6 (PID1172) -|- C7-8 (PID1174) -|- maint. (PID1173)OBIN-CVP (OBIN1000/CYCL750/VNCR2/PRED100), foll. Lymphoma °I-IIIa, C1 (PID2416) -|- C2-8 (PID2417) -|- maint. (PID2419)OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1, first line (PID1645) -|- C2-6 (PID1646) -|- maint. (PID1647)OFAT-CHOP (OFAT300/CYCL750/DOXO50/VNCR2/PRED100), foll. Lymphoma °I-IIIa C1 (PID133) -|- C2-6 (PID149)RITU375 Ind., foll. Lymphoma °I-IIIa A (PID300) -|- maint. B (PID301)RITU375/CHLO6, foll. Lymphoma °I-IIIa, C1 (PID1835) -|- C2-5 (PID1836)RITU375/LENA20, foll. Lymphoma °I-IIIa, C1 (PID1529) -|- C2-6 (PID1530) -|- C7-12 (PID1531) -|- maint. (PID295)RITU375/LENA20, ind. B-NHL ind. (PID309) -|- LENA20 maint. (PID329)ROSEWOOD: OBIN1000/ZANU160, foll. Lymphoma °I-IIIa, C1 (PID2593) -|- C2-6 (PID2594) -|- C7+ (PID2595)ChemotherapyChemo-substanceBendamustineBortezomibCarboplatinCarmustineChlorambucilCyclophosphamideCytarabineDexamethasoneDoxorubicinEpcoritamabEtoposideFludarabineIbrutinibIdelalisibLenalidomideMelphalanMitoxantroneMosunetuzumabObinutuzumabOfatumumabPrednisoloneRituximabTazemetostatVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarboplatinCarmustineChlorambucilCyclophosphamideCytarabineDexamethasoneDoxorubicinEpcoritamabEtoposideFludarabineIbrutinibIdelalisibLenalidomideMelphalanMitoxantroneMosunetuzumabObinutuzumabOfatumumabPrednisoloneRituximabTazemetostatVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarboplatinCarmustineChlorambucilCyclophosphamideCytarabineDexamethasoneDoxorubicinEpcoritamabEtoposideFludarabineIbrutinibIdelalisibLenalidomideMelphalanMitoxantroneMosunetuzumabObinutuzumabOfatumumabPrednisoloneRituximabTazemetostatVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarboplatinCarmustineChlorambucilCyclophosphamideCytarabineDexamethasoneDoxorubicinEpcoritamabEtoposideFludarabineIbrutinibIdelalisibLenalidomideMelphalanMitoxantroneMosunetuzumabObinutuzumabOfatumumabPrednisoloneRituximabTazemetostatVincristineZanubrutinibNo. Substances123456 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneNo. Substances23456789Protocol classificationTherapy classificationalternativecurrent standardindividual (author)Study protocol, currentIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionMaintenanceSalvageTherapy intentionconsolidationcurativecurative or palliativedisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlAstheniaAtrial FibrillationCardiotoxicityConstipationCytokine Release SyndromeDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHepatotoxicityHyperglycemiaHypertensionHypokalemiaHyponatremiaHypophosphatemiaHypotensionIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisNauseaNeuropathyNeurotoxicityNeutropeniaPneumoniaPruritusPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlTumor Lysis SyndromeUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorArdeshna KMBaiocchi RABudde LECzuczman MSDavies AForstpointnerFriedberg JWGhielmini MGopal AKHeidemann WHerold MHerold M HiddemannKirschey SKönig LLinton KLiu E MacManus MMarcus RMartinelli GMorschhauser FMorschhauser F Purev ERobinson KSRummel MJSalles GScholz CWSehn LSehn LHTessoulin BTuscano JMvan Oers MHJWitzig TEZinzani PLDiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomCD20-positives follikuläres Lymphom Grad I-IIIa, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2CD20-positives indolentes B-Non-Hodgkin-Lymphom, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2Foll. L. °I-II, Marginalzonen-L., kleines lymphozyt. L., ECOG 0-2, mind. eine Vortherapiefoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. Lymphom, mind. eine Vortherapie, ECOG 0-2Foll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätFoll. Lymphom, Grad 1-2, Stadium III oder IV mit Therapieindikation, ErstbehandlungFoll. Lymphom, Grad I-III, ECOG 0-2, Erst- und ZweitlinieFoll. Lymphom, Grad I-III, Stadium III oder IV mit Therapieindikation, ECOG 0-2, ErstlinieFoll. Lymphom, Grad I-III, Stadium III und IV, Zweit- bis Drittlinie, ECOG 0-2Foll. Lymphom, Grad I-IIIa, ECOG 0-2, nach Ansprechen auf R-CHOP, R-CVP oder R-FCMFoll. Lymphom, Grad I-IIIa, Stadium I-II, ErstlinientherapieFoll. Lymphom, Grad I-IIIa, Stadium II bis IV mit Therapieindikation, Patienten älter als 50, ErstlinieFoll. Lymphom, Stadium I-IIFoll. Lymphom Grad 1-2, MCL, lymphoplasmozytisches Lymphom, Therapieindikation, Erstlinie ECOG 0-2Foll. Lymphom Grad 1-2, Stadium III und IV, ECOG 0-2, nach Ansprechen auf ErstlinieFoll. Lymphom Grad 1-3a, CD20 pos.,behandlungsbedürftig nach GELF Kriterien, ErstlinientherapieFoll. Lymphom Grad 1-3a, CD20 pos., behandlungsbedürftig nach GELF Kriterien, mind. 1 VortherapieFoll. Lymphom Grad I-III, Progress innerhalb von 6 Monaten oder nach Nichtansprechen auf Rituximab-InduktionFoll. Lymphom °I-III, Std. III u IV oder bulky Std. II, ECOG 0-2, ErstlinieFollikuläres Lymphom, ErstlinieFollikuläres Lymphom, Grad I-III, ECOG 0-2, Erst- und ZweitlinieFollikuläres Lymphom, kleines lymphozytische Lymphom, Erst- bis Fünftlinie, Karnofsky-Index größer 60%Follikuläres Lymphom °I-II, Rituximab-refraktär, ECOG 0-2Follikuläres Lymphom °I-IIIa, nicht vortherapiert, Ann-Arbor Stadium III-IV , oder II mit Bulk über 7 cm, ECOG 0-2Follikuläres Lymphom °I-IIIa, Rezidiviert oder therapierefraktär nach mindestens 2 Vortherapien, inkl. Therapie mit einem Anti-CD20-Antikörperfortgeschrittenes follikuläres Lymphom °I-IIIa, Stadium III oder IV, Erstlinie, ECOG 0-2Indolente B-Non-Hodgkin-Lymphome und Mantelzelllymphom, mind. 1 VortherapieMCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieMCL, follikuläres Lymphom, Grad 1 und 2, Zweitlinie oder höherMCL, follikuläres Lymphom, lymphoplasmozytisches Lymphom, ZweitlinieNon-Hodgkin-Lymphom / Hodgkin LymphomNon-Hodgkin Lymphom, low-grade, nicht-aggressiv, Stadium III-IVRefraktäres oder rezidiviertes follikuläres Lymphom °I-IIIb, Drittlinie, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenRezidiviertes und therapierefraktäres follikuläres Lymphom °I-IIIA, mind. 2 Vortherapien, ECOG 0-2Rituximab refraktäre indolente B-NHL, ECOG 0-2OriginAbteilung für Hämatologie, Onkologie und Tumor Immunologie, Charité Berlin, DeutschlandAddenbrooke's Hospital, Cambridge, EnglandBritish Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada, GADOLIN trialBritish National Lymphoma Investigation, CRC and UCL Cancer Trials Centre, London, UKCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCELESTIMO trialCentre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, GAUSS StudyCentre Hospitalier Unciversitaire, Lille, FrankreichCity of Hope National Medical Center, Duarte, CADepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USADepartment of Radiation Oncology, University of Heidelberg, Heidelberg, GermanyDepartments of Medicine and Immunology, Roswell Park Cancer Institute, Buffallo, USADivision of Clinical Hemato-Oncology, European Institute of Oncology, Milan, ItalyDivision of Clinical Hemato-oncology, European Institute of Oncology, Milan, ItalyEast German Study GroupEORTC, HOVON, NCIC, CTG, BNLI, ALLG, NLGGerman Low-Grade Lymphoma Study GroupGroupe de Recherche sur les formes Injectables et les Technologies Associées, Université de Lille, FranceHelios Klinikum, Hämatologie/Onkologie, Erfurt, Deutschland, Studie OSHO# 19Hospices Civils de Lyon, Université Claude Bernard, Frankreich. PRIMA StudieInstitute of Oncology, Bellinzona, SchweizIRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia, ROSEWOOD trialJames P. Wilmot Cancer Center, University of Rochester, RochesterKings College Hospital, Denmark Hill, London, UK, GALLIUM trialMayo Clinic, Rochester, USANantes Medical University, Nantes, FranceOhio State University, Columbus, Ohio, USAPeter MacCallum Cancer Centre, Melbourne, Australia, TROG 99.03QE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaRoswell Park Cancer Institute, Buffallo, NY, USARoswell Park Cancer Institute, Buffalo, NY, USAStudy Group indolent Lymphomas (StiL)The Christie NHS Foundation Trust, Manchester Cancer Research Centre, UK, EPCORE NHL-1The University of Washington, USA, DAWN studyUC Davis Cancer Center, Sacramento, USAUniversite Lille, Centre Hospitalier Universitaire, Lille, France, RELEVANCE trialUniversite Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France, GALEN trialUniversity Hospital, Ludwig Maximilian University Munich, GALLIUM trialUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversité Lille, Centre Hospitalier Universitaire, Lille, France, RELEVANCE trialProtocols in Revision 74 protocols foundBortezomib 1.3 / Rituximab 375 / Bendamustine 90, indolent B-Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID2678 V1.0)Chlorambucil 10, B-Non-Hodgkin Lymphoma (PID2334 V1.0)DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)Epcoritamab (0.16/0.8/3/48), follicular Lymphoma, cycle 1 (PID2723 V1.1)Epcoritamab 48, follicular Lymphoma, cycle 10+ (PID2726 V1.1)Epcoritamab 48, follicular Lymphoma, cycle 2-3 (PID2724 V1.1)Epcoritamab 48, follicular Lymphoma, cycle 4-9 (PID2725 V1.1)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Ibrutinib 560, follicular lymphoma °I-IIIa (PID2335 V1.0)Idelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308 V1.2)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.1)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.1)Obinutuzumab 1000 - CHOP - Obinutuzumab 1000, follicular lymphoma °I-IIIa, maintenance (PID1173 V1.0)Obinutuzumab 1000 - CHOP - Obinutuzumab 1000, follicular lymphoma °I-IIIa, cycle 7-8 (PID1174 V1.0)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 Maintenance, follicular lymphoma °I-IIIa (PID725 V1.0)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 maintenance, follicular lymphoma °I-IIIa, first-line (PID1647 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1 (PID710 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1, first-line (PID1645 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6 (PID724 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6, first-line (PID1646 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 1 (PID1171 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 2-6 (PID1172 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 1. (PID2416 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, follicular Lymphoma grade I-IIIa, cycle 2-8 (PID2417 V1.1)Obinutuzumab 1000 / Lenalidomide 20 - Obinutuzumab 1000 / Lenalidomide 10 maintenance, follicular Lymphoma °I-IIIa, cycle 7-12 (PID2338 V1.0)Obinutuzumab 1000 / Lenalidomide 20 - Obinutuzumab 1000 maintenance, follicular Lymphoma °I-IIIa, cycle 13-18 (PID2339 V1.0)Obinutuzumab 1000 / Lenalidomide 20, follicular Lymphoma °I-IIIa, cycle 1 (PID2336 V1.0)Obinutuzumab 1000 / Lenalidomide 20, follicular Lymphoma °I-IIIa, cycle 2-6 (PID2337 V1.0)Obinutuzumab 1000 / zanubrutinib 160, follicular Lymphoma °I-IIIa, cycle 1 (PID2593 V1.0)Obinutuzumab 1000 / zanubrutinib 160, follicular Lymphoma °I-IIIa, cycle 2-6 (PID2594 V1.0)Obinutuzumab 1000 / zanubrutinib 160, follicular Lymphoma °I-IIIa, cycle 7+ (PID2595 V1.0)Obinutuzumab 1000, B-non-Hodgkin Lymphoma, maintenance (PID2341 V1.0)Obinutuzumab 1000, B-Non-Hodgkin Lymphoma, Induction (PID2340 V1.0)Obinutuzumab 1000, follicular lymphoma °I-IIIa, maintenance (PID2419 V1.0)Obinutuzumab 1000, follicular Lymphoma °I-IIIa, cycle 7-8 (PID2418 V1.0)Ofatumumab (300/1000), follicular lymphoma grade I-IIIa (PID314 V1.0)Ofatumumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa cycle 2-6 (PID149 V1.1)Ofatumumab 300 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa cycle 1 (PID133 V1.1)R-BOP - Rituximab 375 / Bendamustine 60 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID297 V1.0)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa (PID294 V1.0)R-COP - Rituximab 375 / Cyclophosphamide 400 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID298 V1.0)R-CVP - Rituximab 375 / Cyclophosphamide 1000 / Vincristine 2 / Prednisolone 50 / Radiation, follicular lymphoma grade I-IIIa (PID1575 V1.0)R-CVP - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, follicular lymphoma grade I-IIIa (PID296 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)R-MCP - Rituximab 375 / Mitoxantrone 8 / Chlorambucil 3 / Prednisolone 25, follicular lymphoma grade I-IIIa (PID299 V1.1)RITU375/FLUD25, follicular lymphoma and indolent B-NHL (PID304 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan consolidation, follicular lymphoma grade I-IIIa (PID305 V1.0)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa (PID303 V1.0)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa, second-line (PID306 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270 V1.0)Rituximab 375 / Bortezomib 1.3, Mantle Cell Lymphoma and Follicular Lymphoma (PID278 V1.0)Rituximab 375 / Chlorambucil 6, follicular lymphoma °I-IIIa, cycle 1 (PID1835 V1.0)Rituximab 375 / Chlorambucil 6, Follicular Lymphoma °I-IIIa, cycle 2-5 (PID1836 V1.0)Rituximab 375 / Fludarabine 25 / Cyclophosphamide 200 / Mitoxantrone 8, follicular lymphoma and Mantle Cell Lymphoma (PID272 V1.1)Rituximab 375 / Lenalidomide 10, follicular lymphoma grade I-IIIa, cycle 7-12 (PID1531 V1.0)Rituximab 375 / lenalidomide 20 - Lenalidomide 20 maintenance, indolent B non-Hodgkin Lymphoma induction (PID329 V1.0)Rituximab 375 / Lenalidomide 20, follicular lymphoma grade I-IIIa, cycle 1 (PID1529 V1.0)Rituximab 375 / Lenalidomide 20, follicular lymphoma grade I-IIIa, cycle 2-6 (PID1530 V1.0)Rituximab 375 / Lenalidomide 20, indolent B non-Hodgkin Lymphoma, induction (PID309 V1.0)Rituximab 375 / Radiation, follicular lymphoma (PID2333 V1.0)Rituximab 375 maintenance after first-line, grade I-IIIa follicular lymphoma (PID295 V1.0)Rituximab 375 maintenance after Rituximab induction, follicular lymphoma grade I-IIIa part B (PID301 V1.0)Rituximab 375 maintenance after second-line, grade I-IIIa follicular lymphoma (PID302 V1.0)Rituximab 375 induction, follicular lymphoma grade I-IIIa part A (PID300 V1.0)Study - CELESTIMO - Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 2,4,6,8,10,12 (PID2079 V1.0)Study - CELESTIMO - Mosunetuzumab (1/2/30), Follicular Lymphoma grade I-IIIa, cycle 1 (PID2075 V1.0)Study - CELESTIMO - Mosunetuzumab 30/ Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 2-12 (PID2076 V1.0)Study - CELESTIMO - Rituximab 375 / Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 1 (PID2077 V1.0)Study - CELESTIMO - Rituximab 375 / Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 3,5,7,9,11 (PID2078 V1.0)Tazemetostat 800, follicular Lymphoma (PID2829 V1.0)
